Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2025-07-18EMA Authorised: Fampridine Accord (Fampridine) — Accord Healthcare S.L.U.
The European Medicines Agency authorised Fampridine Accord (fampridine) by Accord Healthcare S.L.U. for use in multiple sclerosis.
-
FDA approval · 2025-06-03FDA Approved: BACLOFEN — Supplemental Application (Advagen Pharma Ltd)
FDA approves a supplemental application for Baclofen from Advagen Pharma Ltd.
-
FDA approval · 2025-05-16FDA Approved: GLATIRAMER ACETATE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for glatiramer acetate from Sun Pharmaceutical Industries, expanding the approval of a generic p…
-
FDA approval · 2025-05-16FDA Approved: GLATIRAMER ACETATE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for glatiramer acetate submitted by Sun Pharmaceutical Industries, Inc. This action approves cha…
-
EMA approval · 2025-05-15EMA Authorised: Dimethyl fumarate Mylan (dimethyl fumarate) — Mylan Ireland Limited
EMA authorised Dimethyl fumarate Mylan for the treatment of multiple sclerosis. The marketing authorization holder is Mylan Ireland Limited.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-05-07FDA Approved: GLATIRAMER ACETATE — Original Application (Italfarmaco SpA)
The FDA approved Italfarmaco SpA's generic Glatiramer acetate via an Original Application (ANDA 208468). The product is for the treatment of…
-
FDA approval · 2025-04-28FDA Approved: FINGOLIMOD — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for fingolimod submitted by Zydus Lifesciences Limited (ANDA 207994).
-
FDA approval · 2025-04-07FDA Approved: TERIFLUNOMIDE — Original Application (CONCORD BIOTECH LIMITED)
FDA approves a generic teriflunomide under an Original Application by Concord Biotech Limited.
-
FDA approval · 2025-03-18FDA Approved: TYSABRI — Supplemental Application (Biogen Inc.)
FDA approved Biogen's supplemental application for TYSABRI (natalizumab), leading to labeling changes under a supplemental submission. The d…
-
FDA approval · 2025-03-13FDA Approved: TERIFLUNOMIDE — Supplemental Application (Teva Pharmaceuticals, Inc.)
The FDA granted a supplemental approval for teriflunomide from Teva Pharmaceuticals, Inc.
-
FDA approval · 2025-03-13FDA Approved: TERIFLUNOMIDE — Supplemental Application (Accord Healthcare Inc.)
The FDA approved a supplemental application for the generic Teriflunomide from Accord Healthcare Inc.
-
FDA approval · 2025-03-07FDA Approved: GLATOPA — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for GLATOPA, Sandoz's generic glatiramer acetate. This product is used for treating multiple scl…
-
FDA approval · 2025-03-07FDA Approved: GLATOPA — Supplemental Application (Sandoz Inc)
FDA approves GLATOPA (glatiramer acetate) under a supplemental application by Sandoz, providing a generic option for multiple sclerosis. The…
-
FDA approval · 2025-03-03FDA Approved: TIZANIDINE — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for tizanidine submitted by Apotex Corp. This action approves the changes described in the supplemen…
-
FDA approval · 2025-02-19FDA Approved: FINGOLIMOD — Supplemental Application (Ascend Laboratories, LLC)
FDA approved Ascend Laboratories, LLC's supplemental application for fingolimod hydrochloride (generic fingolimod), expanding access for tre…
-
EMA approval · 2025-02-13EMA Authorised: Dimethyl fumarate Neuraxpharm (dimethyl fumarate) — Neuraxpharm Pharmaceuticals S.L.
The European Medicines Agency authorised Dimethyl fumarate from Neuraxpharm Pharmaceuticals S.L. for the treatment of multiple sclerosis.
-
FDA approval · 2025-01-29FDA Approved: TERIFLUNOMIDE — Supplemental Application (Camber Pharmaceuticals, Inc.)
The FDA approved Camber Pharmaceuticals’ supplemental application to authorize a generic teriflunomide product for use in treating multiple …
-
FDA approval · 2025-01-28FDA Approved: TASCENSO ODT — Supplemental Application (Cycle Pharmaceuticals Ltd)
FDA approved a supplemental application to add TASCENSO ODT (fingolimod lauryl sulfate) as an orally disintegrating tablet form, expanding f…
-
FDA approval · 2025-01-22FDA Approved: COPAXONE — Supplemental Application (Teva Neuroscience, Inc.)
FDA approved a supplemental application for COPAXONE (glatiramer acetate) by Teva Neuroscience, Inc. The document indicates approval of a su…
-
FDA approval · 2025-01-22FDA Approved: FINGOLIMOD — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Fingolimod from Aurobindo Pharma Limited, approving a generic fingolimod product. The approval c…
-
FDA approval · 2025-01-22FDA Approved: FINGOLIMOD — Supplemental Application (Dr. Reddy's Laboratories Inc)
FDA approved a supplemental application for Fingolimod filed by Dr. Reddy's Laboratories, indicating regulatory approval for a change relate…
-
FDA approval · 2025-01-22FDA Approved: DIMETHYL FUMARATE — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved Glenmark Pharmaceuticals' supplemental application for dimethyl fumarate (generic version) under ANDA210309. This marks regulat…
-
FDA approval · 2025-01-22FDA Approved: FINGOLIMOD — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
The FDA approved a supplemental application for fingolimod submitted by Glenmark Pharmaceuticals Inc., USA, updating the existing approval f…
-
FDA approval · 2025-01-22FDA Approved: FINGOLIMOD — Supplemental Application (Apotex Corp.)
FDA approves a supplemental application for fingolimod by Apotex Corp., enabling the manufacture and distribution of a generic fingolimod pr…
-
EMA approval · 2025-01-06EMA Authorised: Tecfidera (dimethyl fumarate) — Biogen Netherlands B.V.
The EMA has authorised Tecfidera (dimethyl fumarate) for use in multiple sclerosis; the marketing authorisation holder is Biogen Netherlands…